Newly identified gene mutation has potential for the development of more effective treatment of Schizophrenia

[Guest guest]

Contact: Caoimhe Ní Lochlainn

communications@...

003-531-896-2310

Trinity College Dublin

Newly identified gene mutation has potential for the development of more

effective treatment of Schizophrenia

In a major advance for schizophrenia research, an international team of

scientists led by the University of California, San Diego School of Medicine and

involving Trinity College Dublin researchers has identified a gene mutation

strongly linked to schizophrenia that may be an important new target for the

development of drug therapies. The findings are just published in the online

issue of the journal Nature.

Schizophrenia is a chronic, severe and disabling brain disorder, with symptoms

that include hallucinations, delusions and thought disorder. Schizophrenia is

believed to be caused by environmental and genetic factors, most notably the

latter: the illness occurs in 1% of the general population, or 10 % of people

who have a first-degree relative with the disorder, such as a parent or sibling.

Current therapies are only partially effective with little progress being made

in identifying effective new treatments over several decades.

In the last three years researchers have discovered that rare mutations at many

locations in the human genome resulted in significantly higher risk of

schizophrenia. These mutations consisted of copy number variants or CNVs

& #8722;a type of genetic variation in which the number of copies of a gene

differs between individuals. The findings were the first conclusive evidence

that rare mutations can cause schizophrenia, but this did not identify the

specific genes involved.

Professor Aiden Corvin of the Psychosis Research Group at Trinity College

Dublin, funded by Science Foundation Ireland and the Wellcome Trust, and an

author on this paper, describes that the latest study goes substantially

further.

Researchers scanned for CNVs in the genomes of 8,290 individuals with diagnosed

cases of schizophrenia and 7,431 healthy controls. The study confirmed CNVs

identified in earlier studies, but uncovered an important new finding:

duplications at the tip of chromosome 7q were detected in individuals with

schizophrenia at a rate 14 times higher than in healthy individuals. These

duplications impact a gene coding for the brain receptor VIPR2.

Formally known as the Vasoactive Intestinal Peptide Receptor 2, VIPR2 is

expressed in the nervous system, including in the brain, blood vessels and

gastrointestinal tract. Previous studies have shown that VIPR2 helps to regulate

the formation and activity of neurons in the brain. In mice, VIPR2 also has been

found to play important roles in behavioral processes, including learning and

timing of daily activity. The study next measured expression of the VIPR2 gene

in blood cells from patients, they found that individuals with mutations had

greater expression of VIPR2 and greater activity of the receptor.

" This suggests that the mutations increase signaling in the Vasoactive

Intestinal Peptide pathway, " says Professor Corvin. " We know that this activity

can be modulated by synthetic peptides (compounds where amino acids are linked

together) and the next step is to see if these compounds have a therapeutic

effect in mice or in cultured human cells that carry the VIPR2 gene mutation. "

###

The Psychosis Research Group at Trinity College Dublin were involved in the

study design, analysis and data interpretation. Irish patients and their

families from Trinity teaching hospitals contributed to the original test sample

of 802 cases and 742 controls (along with participants from Columbia University,

Harvard, NYU, McLean and University of Washington medical teaching hospitals).

The larger replication set of approximately 8,290 cases and controls also

included Irish participants.

The global collaborative research was led by assistant professor of psychiatry

and cellular and molecular medicine, Sebat, at the University of

California, San Diego School of Medicine.